Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

78.95 -2.23 (-2.75%)
Official Closing Price Updated: 7:00 PM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
The 3 Best Defensive Stocks for Uncertain Times
These are the best defensive stocks to buy as they represent low beta names and companies with robust fundamentals and cash flows. 
Via InvestorPlace
3 S&P stocks with growth to weather a downturn
S&P 500 components Broadcom, McCormick and Merck stocks are diverse stocks worth tracking for investors seeking strong earnings and dividend growth. 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
10 Analysts Have This to Say About Merck & Co
Via Benzinga
Merck & Co Unusual Options Activity For November 03
Via Benzinga
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
There's a lot more at stake than bragging rights. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Qualcomm, Merck And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
A Look Into Merck & Co Inc's Price Over Earnings
Via Benzinga
7 Biotech Stocks to Buy for Big-Time Gains
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research. 
Via InvestorPlace
7 Safe Stocks to Buy if You Think Q3’s Gangbuster Growth Won’t Last
Although the Q3 U.S. GDP print came in much hotter than expected, the momentum might not last, thus incentivizing safe stocks. 
Via InvestorPlace
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients wi 
Via Benzinga
Merck to Participate in the Jefferies London Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Mizuho's Top Stock Picks For November Revealed
As trading for November begins, Mizuho recommends a few stocks for investors to consider. 
Via Benzinga
Down 84% From Its Peak. Is It Finally Time to Buy Moderna?
The vaccine developer's huge profits have turned into heavy losses. 
Via The Motley Fool
3 Trustworthy Blue-Chip Stocks to Buy Now
Considering the economic and geopolitical uncertainty, seek safety in these blue-chip stocks to buy with earnings and dividend growth. 
Via InvestorPlace
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
3 Dividend Stocks That Could Raise Their Payouts in November
Should you add these income-generating stocks to your portfolio? 
Via The Motley Fool
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
Merck's Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda, in combination with gemcitabine and cisplatin, for locally advanced unresectable or  
Via Benzinga
Exposures Product Safety
Merck to Participate in the UBS BioPharma Conference
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
In due time, its new partnership with Daiichi Sankyo could be massive. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.